MIRM at a glance
Mirum Pharmaceuticals, Inc. (MIRM, SEC CIK 1759425) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 28, 2026 and Form 4 insider filings as recently as October 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Mirum Pharmaceuticals, Inc. (MIRM) reported revenue of $521.3 million (up 54.7% from FY2024) and a net loss of $23.4 million. Diluted EPS was -$0.47.
- As of June 30, 2026, 30 institutional investment managers tracked by SignalX reported holding Mirum Pharmaceuticals, Inc. (MIRM) shares worth $3.0 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by BJERKHOLT ERIC on September 14, 2026 of 9,943 shares at $98.37 per share.
- In the last 90 days, MIRM insiders reported 0 open-market purchases ($0) and 10 open-market sales ($10.8M) on Form 4, a net sale of $10.8M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $521.3M
- +54.7% vs prior year
- Insiders · 90 days
- 0 buys · 10 sells
- Net −$10.8M
- 13F holders
- 30 funds
- $3.0B · −1 vs prior quarter
- Latest 8-K
- Sep 28, 2026
- Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core biopharma focused on rare diseases with three approved medicines: Livmarli, Cholbam, Ctexli
- Acquired asset portfolios in 2023-2026: Travere’s bile acid medicines and Bluejay’s brelovitug for hepatitis D treatment
- Strategic expansion into chronic HDV with brelovitug advancing in global Phase 3 AZURE program, topline data expected H2 2026
- Livmarli approved in multiple countries for ALGS and PFIC; pursuing expanded indications with EXPAND Phase 3 study (results Q4 2026)
- Brelovitug Phase 2 showed 100% virologic response at 48 weeks, granted FDA Breakthrough and EMA PRIME designations
Risk Factors
- Regulatory risk CREATES Act compliance, sample provision obligations for generics under December 2019 law
- Geopolitical/macro exposure in EU and U.S. orphan drug exclusivity potentially shortened by EU legislative proposals
- Operational risk integration of Bluejay assets/employees critical to brelovitug development, potential disruption if integration fails
- Competitive risk several companies including Shionogi and Harmony Biosciences developing therapies for fragile X syndrome
- Financial risk dependence on key personnel amid fierce competition for talent in Foster City, CA with 369 full-time employees
AI summary of the MIRM 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Q2 revenue $176.2M, up $48.5M YoY from $127.8M
- Livmarli best performer: $128.7M, up $40.6M YoY
- Bile Acid Medicines: $47.5M, up $7.9M YoY
- Operating loss $42.5M vs $5.0M; operating margin -24.1% vs -3.9% YoY
- Cash, equivalents and investments $561.3M vs $391.4M at December 31, 2025; continued net losses expected
Risk Factors
- No newly added risk factor or explicit quarter-over-quarter change identified in the provided excerpt
- EU Health Technology Assessment Regulation expanded to orphan medicines in January 2028 and all centrally authorized medicines in 2030
- Medicaid rebate compliance exposure, including civil monetary penalties for late AMP and best-price submissions
- Volixibat gastrointestinal and liver-safety concerns, including diarrhea in 77% of PBC VANTAGE patients
- Medicare and commercial-payor cost containment threatening coverage, reimbursement, and pricing for approved medicines
AI summary of the MIRM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- FDA approved Atebrioz for FOP patients aged 12+, enabling U.S. commercialization expected in October 2026
- Atebrioz reduced new HO volume by 3.2 cm³ versus a 24.6 cm³ increase with placebo at Week 24
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Rob Myers, M.D. appointed Chief Medical Officer, expected to start September 21, 2026
- Joanne Quan, M.D. ceased serving as Chief Medical Officer September 2, with employment termination expected October 19, 2026
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results and corporate update announced for quarter ended June 30, 2026
- Full results and management commentary available in Exhibit 99.1
AI summaries of MIRM 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MIRM
Don't miss the next MIRM filing
- Alerts as it files. A push when MIRM files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MIRM, by share count.
- Ask anything. An AI agent that reads every MIRM filing and answers with sources.
MIRM alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Peetz Christopher | M | Oct 6, 2026 | 6,892 | $15.87 |
| Peetz Christopher | M | Oct 6, 2026 | 6,892 | - |
| Peetz Christopher | M | Oct 6, 2026 | 5,305 | $19.19 |
| Peetz Christopher | M | Oct 6, 2026 | 5,305 | - |
| BJERKHOLT ERIC | Sell | Sep 14, 2026 | 9,943 | $98.37 |
| BJERKHOLT ERIC | M | Sep 11, 2026 | 18,333 | - |
| BJERKHOLT ERIC | M | Sep 11, 2026 | 18,333 | - |
| Howe Jolanda | Sell | Sep 2, 2026 | 658 | $100.00 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $336.9M | $521.3M |
| Operating Income | - | -$87.6M | -$22.1M |
| Net Income | -$163.4M | -$87.9M | -$23.4M |
| Op. Margin | - | -26.0% | -4.2% |
| Net Margin | - | -26.1% | -4.5% |
| Balance Sheet | |||
| Total Assets | - | $670.8M | $842.8M |
| Equity | $248.7M | $225.6M | $314.7M |
| ROE | -65.7% | -39.0% | -7.4% |
| Per Share | |||
| EPS | $-4.00 | $-1.85 | $-0.47 |
| Cash Flow | |||
| Operating CF | - | $10.3M | $55.8M |
| CapEx | $109K | $993K | $954K |
Source: XBRL data in Mirum Pharmaceuticals, Inc. (MIRM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate MIRM share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 30 | $2.96B |
| Q1 2026 | 31 | $1.94B |
| Q4 2025 | 26 | $1.36B |
| Q3 2025 | 28 | $1.22B |
| Q2 2025 | 27 | $818.9M |
| Q1 2025 | 23 | $485.9M |
| Q4 2024 | 18 | $338.1M |
| Q3 2024 | 14 | $221.5M |
- FMR LLC (Fidelity)+1.70M (+87%)
- Invesco Ltd+1.08M (+378%)
- Vanguard Portfolio Management LLC+944.9K (+66%)
- T. Rowe Price Group+938.2K (+55%)
- BlackRock+543.5K (+14%)
- Millennium Management−272.4K (-74%)
- Morgan Stanley−173.2K (-33%)
- Vanguard Capital Management LLC−160.7K (-7%)
- Bank of America Corp−160.5K (-22%)
- Renaissance Technologies LLC−139.9K (-24%)
- Citadel Advisors LLC−1.05M
Source: 13F-HR filings on SEC EDGAR (aggregated from 197 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MIRM filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 6, 2026 | - | - | - |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 4 | Sep 15, 2026 | - | - | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| SC 13G | Aug 6, 2026 | - | - | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
MIRM SEC filings: frequently asked questions
Are MIRM insiders buying or selling?
In the last 90 days, Mirum Pharmaceuticals, Inc. (MIRM) officers, directors and 10% owners reported no open-market purchases and 10 open-market sales worth $10.8 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MIRM stock?
As of June 30, 2026, the largest Mirum Pharmaceuticals, Inc. (MIRM) holders among the 13F filers tracked by SignalX were BlackRock ($513.9 million), FMR LLC (Fidelity) ($429.7 million), T. Rowe Price Group ($310.9 million), Vanguard Portfolio Management LLC ($278.3 million), Vanguard Capital Management LLC ($263.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MIRM's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Mirum Pharmaceuticals, Inc. (MIRM) reported revenue of $521.3 million (up 54.7% from FY2024) and a net loss of $23.4 million. Diluted EPS was -$0.47. The figures come from the XBRL data in the 10-K.
What are the main risks in MIRM's latest 10-K?
In the 10-K filed February 25, 2026, Mirum Pharmaceuticals, Inc. (MIRM) flagged: Regulatory risk CREATES Act compliance, sample provision obligations for generics under December 2019 law. Geopolitical/macro exposure in EU and U.S. orphan drug exclusivity potentially shortened by EU legislative proposals. (AI summary of the Risk Factors section.)
What did MIRM report in its latest 8-K?
Mirum Pharmaceuticals, Inc. (MIRM) filed an 8-K on September 28, 2026 reporting Item 8.01 (Other Events). FDA approved Atebrioz for FOP patients aged 12+, enabling U.S. commercialization expected in October 2026.
What are the latest MIRM SEC filings?
Mirum Pharmaceuticals, Inc. (MIRM) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on September 28, 2026 and a Form 4 insider filing on October 6, 2026.
What is MIRM's SEC CIK number?
Mirum Pharmaceuticals, Inc. (MIRM)'s SEC Central Index Key (CIK) is 1759425. EDGAR lists every MIRM filing under that number.
Ask anything about MIRM
The research agent reads MIRM's filings, financials, insider trades and 13F holders, then answers with sources.